MedTrace Logo

Study of Carrageenan's Effect on Insulin Resistance in Humans

NCT02629705 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-10-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether the ingestion of the common food additive carrageenan contributes to insulin resistance and thus to the pathogenesis of type 2 diabetes in humans.

Conditions

Interventions

DIETARY_SUPPLEMENT

Carrageenan

Carrageenan 250 mg bid supplemented to a standard food

DIETARY_SUPPLEMENT

Placebo

Placebo (Mannitol/Aerosil) bid supplemented to a standard food

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Robert Wagner, M.D · University of Tübingen, Department of Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-12-23
Completion
2018-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629705 on ClinicalTrials.gov